Stereotaxis Reports 2021 First Quarter Financial Results

Saint Louis, Missouri, UNITED STATES

ST. LOUIS, May 10, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2021.

“The highlight of the first quarter is Stereotaxis’ return to robust double digit revenue growth with 50% topline growth,” said David Fischel, Chairman and CEO. “The results reflect the initial impact of the first wave of our strategic innovation plan.”

“During the quarter two robotic systems were shipped to hospitals establishing new robotic electrophysiology practices, triggering partial revenue recognition of those systems. Since the quarterly results two months ago, we received an additional purchase order for a robotic system in the United States.”

“We continue to advance a robust innovation pipeline. Our proprietary robotically-navigated magnetic ablation catheter is advancing methodically through required manufacturing and testing processes. We anticipate submitting for regulatory approval in Europe in September and for initiating a US pivotal trial shortly thereafter. At the end of the year we expect to showcase an additional set of innovations that will accelerate adoption of our robotic technology in electrophysiology and beyond. We are confident in the positive impact these innovations will have on patients, physicians, providers, and on Stereotaxis’ financial and strategic foundation.”

“Our commercial and technological progress is being accomplished while remaining prudent with shareholder capital. We continue to invest in the team, infrastructure and projects that are critical for both near and long-term success, and are proud that we are able to do so while maintaining financial discipline.”

2021 First Quarter Financial Results
Revenue for the first quarter of 2021 totaled $8.6 million, a 50% increase from $5.8 million in the prior year first quarter. System revenue of $2.6 million reflects initial revenue recognition on the delivery of a Genesis RMN® system to Europe and a Niobe® system to China. Recurring revenue for the quarter was $5.8 million, compared to $5.5 million in the prior year first quarter.

Gross margin for the first quarter of 2021 was 70% of revenue, with system gross margin of 45% and recurring revenue gross margin of 84%. Operating expenses in the quarter were $7.5 million including $1.4 million in non-cash stock compensation expense. Increased non-cash stock compensation expense is a reflection of an increased stock price and the previously announced CEO Performance Stock Plan. Excluding stock compensation expense, adjusted operating expenses in the current quarter were $6.2 million consistent with the prior year adjusted operating expenses of $6.1 million.

Operating loss and net loss for the first quarter of 2021 were ($1.5) million, compared to ($2.1) million and ($2.0) million respectively in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense, were ($0.2) million compared to ($1.3) million in the prior year. Negative free cash flow for the first quarter was ($0.3) million, compared to ($2.2) million in the prior year first quarter.

Cash Balance and Liquidity
At March 31, 2021, Stereotaxis had cash and cash equivalents, including restricted cash and compensating balances, of $44.1 million.

Forward Looking Expectations
Stereotaxis continues to expect robust double-digit revenue growth in 2021, with robotic system revenue of $10-$20 million. Stereotaxis’ balance sheet allows it to reach profitability without the need for additional financings.

Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, May 10, 2021, at 10:00 a.m. Eastern Time. To access the conference call, dial 1-800-367-2403 (US and Canada) or 1-334-777-6978 (International) and give the participant pass code 6657929. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at

About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependence upon third-party vendors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response to it, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly R. Peery
Chief Financial Officer


 Three Months Ended
March 31,
  2021   2020 
Systems$2,602,512  $- 
Disposables, service and accessories 5,773,516   5,509,711 
Sublease 246,530   246,530 
Total revenue 8,622,558   5,756,241 
Cost of revenue:   
Systems 1,435,535   65,022 
Disposables, service and accessories 924,618   639,863 
Sublease 246,530   246,530 
Total cost of revenue 2,606,683   951,415 
Gross margin 6,015,875   4,804,826 
Operating expenses:   
Research and development 2,367,041   2,109,170 
Sales and marketing 2,947,216   2,915,424 
General and administrative 2,229,739   1,832,726 
Total operating expenses 7,543,996   6,857,320 
Operating loss (1,528,121)  (2,052,494)
Interest income (expense), net (4,276)  80,963 
Net loss$(1,532,397) $(1,971,531)
Cumulative dividend on convertible preferred stock (332,551)  (343,723)
Net loss attributable to common stockholders$(1,864,948) $(2,315,254)
Net loss per share attributed to common stockholder:   
Basic$(0.02) $(0.03)
Diluted$(0.02) $(0.03)
Weighted average number of common shares and equivalents:   
Basic 75,175,412   69,870,040 
Diluted 75,175,412   69,870,040 

 March 31,
 December 31,
Current assets:   
Cash and cash equivalents$42,452,713  $43,939,512 
Restricted cash - current 1,336,000   - 
Compensating cash arrangement 250,919   250,620 
Accounts receivable, net of allowance of $122,570 and $123,614 at 2021 and 2020, respectively 7,290,762   3,515,136 
Inventories, net 3,536,300   3,295,457 
Prepaid expenses and other current assets 1,674,554   1,716,014 
Total current assets 56,541,248   52,716,739 
Property and equipment, net 202,504   195,129 
Restricted cash 93,331   - 
Operating lease right-of-use assets 1,695,664   2,235,442 
Other assets 284,946   308,515 
Total assets$58,817,693  $55,455,825 
Liabilities and stockholders' equity   
Current liabilities:   
Short-term debt$1,914,692  $1,185,058 
Accounts payable 2,270,432   1,608,636 
Accrued liabilities 2,578,298   3,209,235 
Deferred revenue 8,188,296   5,282,770 
Current portion of operating lease liabilities 1,734,699   2,287,487 
Total current liabilities 16,686,417   13,573,186 
Long-term debt 243,617   973,252 
Long-term deferred revenue 1,328,272   548,915 
Other liabilities 210,096   131,231 
Total liabilities 18,468,402   15,226,584 
Series A - Convertible preferred stock:   
Convertible preferred stock, Series A, par value $0.001; 22,408 and 22,513 shares outstanding at 2021 and 2020, respectively 5,578,437   5,605,323 
Stockholders' equity:   
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2021 and 2020 5,610   5,610 
Common stock, par value $0.001; 300,000,000 shares authorized, 74,089,659 and 73,694,203 shares issued at 2021 and 2020, respectively 74,090   73,694 
Additional paid-in capital 524,388,783   522,709,846 
Treasury stock, 4,015 shares at 2021 and 2020 (205,999)  (205,999)
Accumulated deficit (489,491,630)  (487,959,233)
Total stockholders' equity 34,770,854   34,623,918 
Total liabilities and stockholders' equity$58,817,693  $55,455,825